United Kingdom, London, February 20, 2026 – Biocell Ltd announces it has been granted JP patent for OPX – its novel development for prostate cancer prevention. “Hacking metabolic pathways involved in carcinogenesis, reducing our cancer odds cancer can change the healthcare paradigm” said Biocell founder Dr Kevehazi.
“The patented formula is a novel versatile therapeutic and chemo-preventive modulating changes that occur at cellular level during middle age and lead to Benign Prostate Hyperplasia (BPH) in almost half of male population and 1 in 6 Caucasian men that are diagnosed with Prostate cancer. It is especially concerning that 1 in 4 men of African descent are diagnosed with prostate cancer due to genetic predisposition. OPX could be indicated for male demographic at high risk starting in their 30s for cancer risk reduction. When many healthy athletes are diagnosed with advanced stage of prostate cancer worldwide, for example, Sir Chris Hoy- 6 times Olympic gold medalist diagnosed with stage 4 prostate cancer, it is time to ask the question: why not do more instead of just waiting to be diagnosed? Two decades ago, when Biocell founder Dr Laura Mann Kevehazi DMD began early screening for breast cancer due to high-risk family history, a question kept coming up: why are we sitting ducks waiting to discover cancer instead of safely targeting disease at the source and disrupting cancer before it starts?
“Prostate health can impact men health for decades, OPX offers a novel pro-active sustainable and non-toxic therapy to significantly and safely lower their prostate cancer risk and improve fertility and wellbeing. Modulating metabolic pathways demonstrated to drive carcinogenesis, OPX can open a new chapter in men’s health, protecting the prostate health, avoiding the need for invasive prostate exams and surgeries, expanding health span and longevity. OPX has demonstrated high efficacy in androgen-independent cancer xenograft model, as well as very significant sperm improvement in case study.” Dr Kevehazi, Biocell CEO
Lancet Commission on Prostate Cancer (April 2024: Prostate cancer cases are increasing globally, with newly diagnosed cases projected to double from 1.4 million in 2020 to 2.9 million by 2040, with the main increase in east Asia. Prostate Cancer Therapeutics Market reached USD 13.7 billion in 2023 and is expected to reach 28.5 billion by 2032 (Horizon Research)
Biocell Ltd is actively seeking exclusive research and licensing partnerships